2 ASX biotech shares rocketing more than 40% on big news

These two ASX healthcare companies have exciting news for investors today.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX All Ordinaries Index (ASX: XAO) is down 1.25% on Thursday to 8,102.6 points following a Wall Street dive overnight.

The S&P 500 Index (SP: .INX) fell 2.31%, and the Nasdaq Composite Index (NASDAQ: .IXIC) lost 3.64% after two of the world's biggest tech companies revealed their earnings results.

Despite the sea of red today, two ASX biotech shares are shooting the lights out after releasing positive news announcements.

Let's take a look at these two companies and what they've revealed to the market today.

These 2 ASX biotech shares are star performers on Thursday

Amplia Therapeutics Ltd (ASX: ATX)

This ASX biotech share was up 41.94% to 8.8 cents this afternoon and up 12.5% over the past 12 months.

Amplia is an Australian clinical-stage biotech focused on developing two oral drugs that inhibit Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.

Today, the company reported some positive results from its Phase 2a clinical trial.

The trial is investigating a drug called narmafotinib in the treatment of advanced pancreatic cancer.

Amplia said three patients enrolled in the trial had recorded at least a 30% decrease in the overall size of their tumours, as well as no new ones, over a two-month period.

Two other patients have recorded sustained stable disease for a four-month period.

Amplia CEO and managing director Dr Chris Burns said the results were "extremely encouraging".

Dr Burns commented:

We are well on track to reach the efficacy threshold of six confirmed partial or complete responses by the end of this quarter, which will then allow us to restart the trial to recruit the full cohort of fifty patients.

Tissue Repair Ltd (ASX: TRP)

This ASX biotech share is up 59% to 35 cents and trading 12.9% higher over the past 12 months.

Tissue Repair is a clinical-stage biopharmaceutical company developing advanced wound-healing products for chronic wounds and aftercare.

Today, the company revealed it has received approval from the Therapeutic Goods Administration (TGA) for its first advanced wound healing gel product, TR Pro+.

The gel contains Tissue Repair's proprietary active ingredient, Glucoprime (0.1%), which is derived from yeast. The product has been approved in 10g and 50g tubes and 3g sachets.

Tissue Repair says TR Pro+ "represents a new standard in the aftercare of medical and aesthetic procedures".

It said the TGA listing would enable it to promote its scientific and clinical data more broadly.

In a statement, the ASX 200 biotech company said:

Importantly securing general claims around skin healing, repair and regeneration will allow the
Company to significantly expand the indications that it can market the product for including acute
wounds, and a broad range of derm conditions.

Investors in this ASX biotech share are clearly delighted with the news, judging by the skyrocketing share price today.

Tissue Repair launched TR Pro+ a year ago when it had regulatory status as a cosmetic product.

The company reported record sales of TR Pro+ in the third quarter, with 130% quarter-over-quarter growth and distribution expanding to more than 160 clinics.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »